Investor reaction to Vertex data too harsh?
This article was originally published in Scrip
New cystic fibrosis data from Vertex Pharmaceuticals has investors discouraged, pushing the stock down almost 4% to linger near $126 at the end of trading on 23 March, despite the study showing positive results that have confirmed the company's move into Phase III.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.